Drugs facing NCE-1 in 2021

1. List of Bevyxxa drug patents

BEVYXXA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598276 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(3 years from now)

US8557852 PORTOLA PHARMS INC Methods of using crystalline forms of a salt of a factor Xa inhibitor
Sep, 2028

(5 years from now)

US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors
Dec, 2030

(7 years from now)

US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Mar, 2031

(7 years from now)

Do you want to check out BEVYXXA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 2021-06-23

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis; Inhibiting coagulation

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

17

United States

6

China

4

Canada

4

Japan

4

European Union

3

Spain

3

Russia

3

Argentina

3

New Zealand

3

Portugal

2

Hong Kong

2

Korea, Republic of

2

Peru

2

Israel

2

Taiwan

2

Australia

2

South Africa

1

Austria

1

Denmark

1

Brazil

1

Singapore

1

Morocco

1

Nicaragua

1

Costa Rica

1

Ecuador

1

Colombia

2. List of Calquence drug patents

CALQUENCE's oppositions filed in EPO
CALQUENCE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(3 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US11059829 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Do you want to check out CALQUENCE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 2021-10-31

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult p...

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

32

United States

11

Japan

10

European Union

8

Australia

6

China

6

Israel

5

Spain

5

Korea, Republic of

5

Lithuania

5

Hungary

IB

4

IB

4

Denmark

4

RS

4

Poland

4

Canada

4

Croatia

4

Portugal

4

Taiwan

4

Slovenia

3

Morocco

3

Singapore

3

Argentina

EA

3

EA

2

Russia

2

Brazil

2

Ukraine

2

Norway

2

New Zealand

2

Chile

2

Mexico

2

South Africa

1

Hong Kong

1

Austria

1

Dominican Republic

1

Philippines

1

Malaysia

1

Turkey

1

India

1

Moldova, Republic of

1

ME

1

Nicaragua

1

Guatemala

1

Cyprus

1

Peru

1

Costa Rica

1

Ecuador

1

Netherlands

1

Colombia

1

Tunisia

3. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548943 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US9867863 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US10335451 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US10500247 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(6 years from now)

US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(8 years from now)

US11559559 LA JOLLA PHARMA NA
Dec, 2034

(11 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(13 years from now)

Do you want to check out GIAPREZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 2021-12-21

Market Authorisation Date: 21 December, 2017

Treatment: Increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; Increasing blood pressure with an initial rate of about 20 ng/k...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

GIAPREZA family patents

23

United States

4

Japan

3

China

3

Korea, Republic of

3

Australia

3

European Union

2

Brazil

2

Canada

EA

2

EA

1

Spain

1

Denmark

1

RS

1

Poland

1

New Zealand

1

Croatia

1

Cyprus

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Lithuania

1

Slovenia

1

Hungary

4. List of Goprelto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(13 years from now)

Do you want to check out GOPRELTO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 2021-12-14

Market Authorisation Date: 14 December, 2017

Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method for the induction of local anesthesia of the muc...

Dosage: SOLUTION;NASAL

More Information on Dosage

GOPRELTO family patents

14

United States

5. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Apr, 2031

(7 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Nov, 2027

(4 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11311532 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2039

(16 years from now)

US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(17 years from now)

Do you want to check out INGREZZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 2021-04-11

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Method of treating tardive dyskinesia while avoiding concomitant use of ...

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

INGREZZA family patents

59

United States

20

Japan

13

China

12

Australia

11

Canada

EA

10

EA

10

Korea, Republic of

9

Mexico

8

Philippines

6

Singapore

6

European Union

5

Morocco

4

Brazil

4

Israel

3

Spain

3

Denmark

3

Poland

3

Portugal

2

RS

2

Croatia

2

Taiwan

2

Lithuania

2

Slovenia

2

Hungary

1

Malaysia

1

Argentina

1

Cyprus

1

Chile

1

Jordan

1

Colombia

1

Saudi Arabia

1

Tunisia

6. List of Parsabiv drug patents

PARSABIV's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US9701712 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8377880 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8999932 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Feb, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11162500 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US9820938 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US10344765 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

Do you want to check out PARSABIV patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: 2021-02-07

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's patent expiration?
More Information on Dosage

PARSABIV family patents

21

United States

7

European Union

4

China

4

Japan

4

Lithuania

4

Hungary

3

Spain

3

Denmark

3

Poland

3

Singapore

3

Croatia

3

Portugal

3

Slovenia

2

Hong Kong

2

Brazil

2

Canada

2

New Zealand

2

Korea, Republic of

2

Cyprus

2

Peru

2

Israel

2

Taiwan

2

Mexico

2

Australia

2

Costa Rica

2

South Africa

1

Uruguay

1

Philippines

1

Malaysia

1

Turkey

1

RS

1

Russia

1

Ukraine

1

Morocco

1

Argentina

EA

1

EA

1

Norway

1

ME

1

San Marino

1

Chile

1

Jordan

1

Luxembourg

1

Tunisia

7. List of Rhopressa drug patents

RHOPRESSA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(7 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US11618748 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(10 years from now)

Do you want to check out RHOPRESSA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022

Drugs and Companies using NETARSUDIL MESYLATE ingredient

NCE-1 date: 2021-12-18

Market Authorisation Date: 18 December, 2017

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of RHOPRESSA before it's patent expiration?
More Information on Dosage

RHOPRESSA family patents

41

United States

12

Japan

11

Australia

9

European Union

6

Spain

5

Canada

3

China

2

Netherlands

2

Hong Kong

8. List of Rocklatan drug patents

ROCKLATAN's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(7 years from now)

US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US11618748 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(6 years from now)

US11197853 AERIE PHARMS INC Combination therapy
Mar, 2034

(10 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(10 years from now)

Do you want to check out ROCKLATAN patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022
New Combination (NC) Mar 12, 2022

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

NCE-1 date: 2021-12-18

Market Authorisation Date: 12 March, 2019

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ROCKLATAN before it's patent expiration?
More Information on Dosage

ROCKLATAN family patents

41

United States

12

Japan

11

Australia

9

European Union

6

Spain

5

Canada

3

China

2

Netherlands

2

Hong Kong

9. List of Symproic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(3 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(4 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(8 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(9 years from now)

Do you want to check out SYMPROIC patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2022

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: 2021-03-23

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage

SYMPROIC family patents

11

United States

7

Japan

3

Taiwan

3

European Union

2

Spain

2

Denmark

2

Poland

2

China

2

Russia

2

Canada

2

Korea, Republic of

2

Israel

2

Mexico

2

Australia

1

Philippines

1

RS

1

Brazil

1

Ukraine

1

Croatia

1

Portugal

1

South Africa

1

Lithuania

1

Slovenia

1

Hungary

10. List of Trulance drug patents

TRULANCE's oppositions filed in EPO
TRULANCE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(11 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(4 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637451 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Mar, 2022

(1 year, 2 months ago)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(8 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(9 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

Do you want to check out TRULANCE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: 2021-01-19

Market Authorisation Date: 19 January, 2017

Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Chronic idiopathic constipation; Irritable bowel syndrome with constipation

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

TRULANCE family patents

36

United States

9

Japan

8

Australia

8

European Union

7

China

6

Canada

5

Hong Kong

4

Spain

EA

3

EA

1

Korea, Republic of

1

Germany

1

Cyprus

1

Brazil

1

Portugal

1

Israel

1

Denmark

11. List of Vosevi drug patents

VOSEVI's oppositions filed in EPO
VOSEVI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(5 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
May, 2033

(9 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US11338007 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Jun, 2037

(14 years from now)

US11338007

(Pediatric)

GILEAD SCIENCES INC Combination formulation of three antiviral compounds
Dec, 2037

(14 years from now)

Do you want to check out VOSEVI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 2021-07-18

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...

Dosage: TABLET;ORAL

More Information on Dosage

VOSEVI family patents

106

United States

36

Japan

36

European Union

26

Korea, Republic of

23

China

22

Australia

21

Spain

20

Hong Kong

20

Canada

20

Singapore

20

New Zealand

17

Portugal

16

Israel

15

Poland

EA

15

EA

15

Taiwan

15

Mexico

15

Slovenia

14

Brazil

12

Argentina

11

Chile

9

Uruguay

9

Denmark

9

Croatia

9

Cyprus

9

Hungary

8

Philippines

8

Colombia

7

RS

7

Peru

7

Ecuador

7

South Africa

7

Lithuania

6

Moldova, Republic of

6

Ukraine

6

ME

6

Costa Rica

5

Malaysia

5

Morocco

4

Russia

4

San Marino

3

Germany

AP

2

AP

1

Turkey

1

India

1

Norway

1

Netherlands

1

Luxembourg

12. List of Xadago drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8278485 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Jun, 2027

(4 years from now)

US8076515 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283380 MDD US Methods for treatment of parkinson's disease
Mar, 2031

(7 years from now)

Do you want to check out XADAGO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 21, 2022

Drugs and Companies using SAFINAMIDE MESYLATE ingredient

NCE-1 date: 2021-03-21

Market Authorisation Date: 21 March, 2017

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes

Dosage: TABLET;ORAL

More Information on Dosage

XADAGO family patents

6

United States

6

European Union

5

Norway

4

Spain

4

Denmark

4

Poland

4

China

4

Japan

4

Korea, Republic of

4

Cyprus

4

Portugal

4

Slovenia

3

New Zealand

3

Israel

3

Taiwan

3

Mexico

2

RS

2

Brazil

2

Canada

2

Argentina

EA

2

EA

2

Croatia

2

Australia

2

Hungary

IB

1

IB

1

Austria

1

Hong Kong

1

Germany

1

Russia

1

Netherlands

1

Lithuania

1

Luxembourg

13. List of Xepi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6335447 FERRER INTERNACIONAL Quinolonecarboxylic acid derivatives or salts thereof
Nov, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399014 FERRER INTERNACIONAL Pharmaceutical topical compositions
Dec, 2029

(6 years from now)

US9180200 FERRER INTERNACIONAL Pharmaceutical topical compositions
Jan, 2032

(8 years from now)

Do you want to check out XEPI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 11, 2022

Drugs and Companies using OZENOXACIN ingredient

NCE-1 date: 2021-12-11

Market Authorisation Date: 11 December, 2017

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM;TOPICAL

More Information on Dosage

XEPI family patents

5

United States

4

European Union

3

Korea, Republic of

2

Canada

2

Japan

2

Chile

2

Taiwan

2

Mexico

1

Uruguay

1

Spain

1

Hong Kong

1

Philippines

1

Denmark

1

Poland

1

China

1

Russia

1

Brazil

1

Argentina

1

Cyprus

1

Portugal

1

Australia

1

Netherlands

1

Slovenia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in